Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 5.1% Today

What is Bristol-Myers Squibb Company?

Bristol Myers Squibb (BMY) is a pharmaceutical company known for its innovative treatments in various therapeutic areas. Today, the stock experienced a strong bullish movement in the market.

Why is Bristol-Myers Squibb Company going up?

BMY stock is up 5.1% on Apr 30, 2026 19:56

• The bullish movement of BMY could be attributed to the positive outlook surrounding its schizophrenia drug Cobenfy, positioned as a safer alternative for Alzheimer's disease psychosis treatment, potentially attracting investor interest in the company's pipeline and future prospects.
• The delayed pivotal Phase 3 ADEPT-2 study data for Cobenfy, expected later this year, might have created anticipation and excitement among investors, leading to increased buying activity of BMY shares.
• The strong performance of competitors like ALNYLAM PHARMACEUTICALS and Eli Lilly and Company, as indicated by their positive earnings reports and revenue growth, could have positively influenced market sentiment towards pharmaceutical stocks, including BMY, contributing to its bullish movement today.

BMY Price Chart

BMY Technical Analysis

BMY News

BMS positions Cobenfy as safer alternative ahead of pivotal Alzheimer’s psychosis readout

Bristol Myers Squibb is promoting its schizophrenia drug Cobenfy as a potentially safer treatment for Alzheimer's disease psychosis, a condition affecting 30-50% of Alzheimer's patients for which no approved treatments currently exist. Unlike existing antipsychotics and some Alzheimer's therapies that carry boxed warnings for elderly patients, Cobenfy does not have such warnings, making safety a key differentiator. The company is awaiting pivotal Phase 3 ADEPT-2 study data later this year, which was delayed in late 2025 due to "irregularities" at some study sites.

https://www.biospace.com/business/bms-positions-cobenfy-as-safer-alternative-ahead-of-pivotal-alzheimers-psychosis-readout

Acrivon Therapeutics (NASDAQ: ACRV) sets 2026 virtual meeting, director and auditor votes

Acrivon Therapeutics will hold its 2026 Annual Meeting of Stockholders virtually on June 17, 2026, at 1:00 PM Eastern Time. Stockholders are asked to elect two Class I directors, Michael Tomsicek and Charles Baum, for three-year terms and to ratify the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. The Board recommends voting "FOR" all nominees and auditor ratification, outlining its governance structure, director independence, and executive compensation data for 2025.

https://www.stocktitan.net/sec-filings/ACRV/def-14a-acrivon-therapeutics-inc-definitive-proxy-statement-ecdd37ade7b1.html

ALNYLAM PHARMACEUTICALS ($ALNY) Releases Q1 2026 Earnings

ALNYLAM PHARMACEUTICALS ($ALNY) announced strong Q1 2026 earnings, beating analyst estimates with $1.99 per share and revenues of $1,167,180,000. Despite positive analyst ratings and price targets, insider trading activity shows significant sales by executives, while hedge fund activity indicates mixed sentiment with major portfolio adjustments.

https://www.quiverquant.com/news/ALNYLAM+PHARMACEUTICALS+%28%24ALNY%29+Releases+Q1+2026+Earnings

Lexeo Therapeutics (NASDAQ: LXEO) details 2026 virtual meeting, board elections and pay

Lexeo Therapeutics, Inc. (NASDAQ: LXEO) will host its 2026 annual stockholders meeting virtually on June 25, 2026, where shareholders will vote on the election of three Class III directors and the ratification of KPMG LLP as the independent registered public accounting firm. The proxy statement provides details on director independence, non-employee director compensation, and executive pay, including 2026 base salaries and target bonuses for CEO R. Nolan Townsend and CFO Louis Tamayo. It also outlines the severance terms for executives in the event of a change in control, ensuring a transparent overview of corporate governance and compensation practices.

https://www.stocktitan.net/sec-filings/LXEO/def-14a-lexeo-therapeutics-inc-definitive-proxy-statement-93cdff369378.html

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines

Eli Lilly and Company reported strong first-quarter 2026 financial results, with revenue increasing 56% to $19.8 billion and EPS rising 170% to $8.26. The company raised its full-year 2026 revenue guidance to between $82.0 billion and $85.0 billion, and non-GAAP EPS guidance to $35.50 to $37.00. Key drivers included robust sales of Mounjaro and Zepbound, along with significant progress in regulatory approvals, clinical trials, and business development activities, including the FDA approval of Foundayo for obesity.

https://www.prnewswire.com/news-releases/lilly-reports-first-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-momentum-of-new-medicines-302758113.html

Trending Today

Roku Inc. ($ROKU) Stock Forecast: Up 5.1% Today

Twilio Inc. Class A ($TWLO) Stock Forecast: Up 5.2% Today

eBay Inc. ($EBAY) Stock Forecast: Up 6.2% Today

Texas Instruments Incorporated ($TXN) Stock Forecast: Up 5.3% Today

Eli Lilly and Company ($LLY) Stock Forecast: Up 9.7% Today

Altria Group Inc. ($MO) Stock Forecast: Up 6.0% Today

Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 5.1% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 6.0% Today

O'Reilly Automotive Inc. ($ORLY) Stock Forecast: Up 8.7% Today

IPG Photonics Corporation ($IPGP) Stock Forecast: Up 5.4% Today

Bristol-Myers Squibb Company Price History

30.03.2026 - BMY Stock was up 5.1%

• The bullish movement of BMY could be attributed to the positive outlook surrounding its schizophrenia drug Cobenfy, positioned as a safer alternative for Alzheimer's disease psychosis treatment, potentially attracting investor interest in the company's pipeline and future prospects.
• The delayed pivotal Phase 3 ADEPT-2 study data for Cobenfy, expected later this year, might have created anticipation and excitement among investors, leading to increased buying activity of BMY shares.
• The strong performance of competitors like ALNYLAM PHARMACEUTICALS and Eli Lilly and Company, as indicated by their positive earnings reports and revenue growth, could have positively influenced market sentiment towards pharmaceutical stocks, including BMY, contributing to its bullish movement today.

05.01.2026 - BMY Stock was up 5.7%

• Bristol Myers Squibb's stock surged due to its fourth-quarter earnings surpassing analyst expectations, showcasing a strong financial performance.
• Investor excitement was further boosted by the positive outlook provided by the company, reflecting confidence in its future growth prospects.
• Revenue growth, particularly driven by successful immuno-oncology treatments, helped offset the decline in sales of older drugs, contributing to overall positive market sentiment.
• The impressive performance in Q4 2025 and the promising outlook for 2026 underscored Bristol Myers Squibb's resilience in adapting to market changes and solidifying its position in the pharmaceutical industry.

05.01.2026 - BMY Stock was up 3.2%

• Despite disappointments with Eliquis and Cobenfy, Bristol Myers Squibb's strong fourth-quarter earnings report and revenue beat have propelled its stock to a bullish movement.
• The company's focus on its Growth Portfolio, featuring drugs like Opdivo and Reblozyl, has driven significant revenue growth and instilled confidence in investors.
• Bristol Myers Squibb's strategic approach to leaning on new products and potential M&A opportunities to expand its therapeutic areas has resonated well with the market, leading to the positive market movement.
• The company's ability to exceed analyst expectations and provide an optimistic outlook for future revenues has further fueled investor excitement and contributed to the bullish trend in its stock price.

03.11.2025 - BMY Stock was up 5.5%

• Bristol Myers Squibb's stock surged by approximately 6% after announcing a delay in the readout of a crucial Phase 3 clinical trial for its drug Cobenfy, designed for Alzheimer's disease psychosis. The market reacted positively to this unexpected news, indicating investor optimism about the drug's potential success.
• The decision to enroll more patients in the clinical trial demonstrates the company's commitment to ensuring data integrity and addressing unmet medical needs in Alzheimer's disease, further boosting investor confidence in Bristol Myers Squibb.
• Additionally, the successful achievement of a drug discovery milestone in collaboration with Terray Therapeutics showcases Bristol Myers Squibb's dedication to leveraging innovative technologies like AI to accelerate drug discovery processes, potentially leading to the development of novel and effective treatments.
• The continuation of the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer's Disease, despite site irregularities, underlines Bristol Myers Squibb's adherence to rigorous clinical standards and its proactive approach to resolving challenges in clinical trials, reinforcing investor trust in the company's research and development efforts.

03.11.2025 - BMY Stock was up 5.1%

• BMY's stock surged after a positive update on its late-stage clinical trial for treating psychosis associated with Alzheimer’s disease, signaling progress in its research endeavors.
• A collaboration milestone with Terray Therapeutics highlights BMY's utilization of AI-enabled drug discovery technologies to accelerate small molecule drug development, potentially enhancing investor confidence.
• Despite delays in the Adept-2 study for Cobenfy in Alzheimer's psychosis, efforts to rectify site irregularities and continue enrolling new patients demonstrate BMY's commitment to upholding clinical standards and addressing medical needs, possibly contributing to the stock's bullish performance.

05.00.2026 - BMY Stock was down 1.7%

• Increased investments by Railway Pension Investments Ltd and CWA Asset Management Group LLC in Bristol Myers Squibb (BMY) may have hinted at uncertainties about the company's future performance, influencing the bearish trajectory.
• While Bristol Myers Squibb exceeded Q3 earnings and revenue projections and raised its dividend, market sentiments may have been dampened by apprehensions regarding the company's growth outlook.
• Favorable results from Zenas BioPharma's Phase 3 trial and the thriving Hair Loss Treatment Market could have drawn investor attention away from Bristol Myers Squibb, impacting its stock trajectory.
• The optimistic forecast for the pharmaceutical sector, evidenced by growth prospects in the aminoglycosides market, might have steered investor focus elsewhere from Bristol Myers Squibb, contributing to the downward movement in its stock.

20.02.2026 - BMY Stock was down 2.7%

• Union Bancaire Privee UBP SA, Mirabella Financial Services LLP, and CIBC Bancorp USA Inc. all increased their stakes in BMY, signaling confidence in the company's long-term prospects despite recent stock price fluctuations.
• Bristol Myers Squibb reported quarterly earnings that missed analyst estimates but maintained its full-year EPS guidance and announced a quarterly dividend, which might have contributed to the bearish market movement.
• The news about ImmunityBio's cancer therapy Anktiva gaining recognition and Evotec's AI-driven research reaching a critical milestone with a drug developed in partnership with BMY could have diverted investor attention from BMY, impacting its stock performance negatively.
• Despite positive developments in the healthcare sector, including advancements in cancer therapies, BMY's stock faced downward pressure, possibly due to profit-taking or market uncertainties surrounding its recent financial results.

14.10.2025 - BMY Stock was down 5.5%

• Despite strong performance in the third quarter, Bristol Myers Squibb experienced a bearish movement, possibly due to profit-taking by investors after a recent 7.2% increase in share price.
• Jim Cramer's decision to back off on Bristol-Myers might have influenced investor sentiment, leading to a sell-off in the stock.
• The market may be shifting focus towards other promising opportunities like Baidu and Alibaba, as mentioned by Jim Cramer, diverting attention away from Bristol-Myers Squibb in the short term.

06.01.2026 - BMY Stock was up 5.1%

• Despite industry challenges, Bristol Myers Squibb (BMY) saw a strong bullish movement in its stock price.
• Investor optimism towards BMY is likely driven by the company surpassing analysts' expectations for adjusted earnings and revenue in the fourth quarter.
• The positive sentiment towards BMY could also be linked to the upcoming conference call to discuss financial results, hinting at potential positive developments or strategic plans.
• This upward trend may indicate that investors are focusing on Bristol Myers Squibb's resilience and ability to navigate industry challenges, rather than broader market uncertainties impacting other pharmaceutical companies.

30.09.2025 - BMY Stock was up 5.0%

• BMY saw a positive uptrend after surpassing Q3 earnings and sales expectations, boosted by the success of key drugs including Opdivo, Reblozyl, and Breyanzi.
• The decision to increase its 2025 sales forecast despite decreases in older drugs demonstrates confidence in its newer treatments and overall growth strategy.
• Market sentiment is favorable towards BMY's performance, especially as the growing demand for cutting-edge medications like Opdivo and Camzyos offsets declines in older products.

06.00.2026 - BMY Stock was up 5.1%

• A recent collaboration between Gilead and OncoNano Medicine utilizing OncoNano's drug delivery platform may have attracted investor interest in the pharmaceutical sector, benefiting companies like Bristol Myers Squibb.
• Robeco Institutional Asset Management B.V. raised its stake in BMY by 6.4% during the 3rd quarter, indicating a growing confidence in the company's future prospects, potentially influencing the bullish movement.
• Despite some reduction in BMY position by D.A. Davidson & CO., the overall positive sentiment towards the company, especially post exceeding earnings estimates and offering strong guidance, likely overshadowed this sell-off.
• The comparison between Zenas Biopharma's obexelimab and Amgen's Uplizna in the Phase 3 trial may have highlighted Bristol Myers Squibb's competitive edge or potential in the pharmaceutical market, fueling investor optimism and driving the stock price upwards.

30.03.2026 - BMY Stock was up 4.5%

• Bristol Myers Squibb (BMY) experienced a strong bullish movement today, likely driven by its higher-than-expected quarterly profit fueled by robust sales of its blood thinner Eliquis and newer cancer treatments.
• The positive market sentiment towards BMY could also be influenced by the reaffirmation of its 2026 financial outlook and progress on a $2 billion cost-cutting program, showcasing strong financial management.
• Additionally, the overall bullish trend in the pharmaceutical sector, as evidenced by Merck's earnings beat and raised guidance, may have contributed to the positive movement in BMY's stock price.
• Investors are likely optimistic about BMY's future prospects, especially with the company's focus on innovative treatments and maintaining a competitive edge in the market.